FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3211232292> ?p ?o ?g. }

• W3211232292 abstract "Abstract To evaluate the efficacy and safety of atropine 0.01% eye drops for myopia control in a multicentric pediatric Spanish cohort. An interventional, prospective, multicenter study was designed. Children aged between 6 and 14 years, with myopia between − 2.00 D to − 6.00 D, astigmatism < 1.50 D and documented previous annual progression greater than − 0.5 D (cycloplegic spherical equivalent, SE) were included. Once nightly atropine 0.01% eye drops in each eye were prescribed to all participants for 12 months. Age, gender, ethnicity and iris color were registered. All patients underwent the same follow-up protocol in every center: baseline visit, telephone consultation 2 weeks later and office controls at 4, 8 and 12 months. At each visit, best-corrected visual acuity, and cycloplegic autorefraction were assessed. Axial length (AL), anterior chamber depth and pupil diameter were measured on an IOL Master (Carl Zeiss Meditec, Inc, Dublin, CA). Adverse effects were registered in a specific questionnaire. Mean changes in cycloplegic SE and AL in the 12 months follow-up were analyzed. SE progression during treatment was compared with the SE progression in the year before enrollment for each patient. Correlation between SE and AL, and annual progression distribution were evaluated. Progression risk factors were analyzed by multivariate logistic regression analyses. Of the 105 recruited children, 92 completed the treatment. Mean SE and AL changes were − 0.44 ± 0.41 D and 0.27 ± 0.20 mm respectively. Mean SE progression was lower than the year before treatment (− 0.44 ± 0.41 D versus − 1.01 ± 0.38 D; p < 0.0001). An inverse correlation between SE progression and AL progression (r: − 0.42; p < 0.0001) was found. Fifty-seven patients (62%) had a SE progression less than − 0.50 D. No risk factors associated with progression could be identified in multivariate analyses. Mean pupil diameter increment at 12-months visit was 0.74 ± 1.76 mm. The adverse effects were mild and infrequent, and decreased over the time. Atropine 0.01% is effective and safe for myopia progression control in a multicentric Spanish children cohort. We believe this efficacy might be extensible to the myopic pediatric population from Western countries with similar social and demographic features. More studies about myopia progression risk factors among atropine treated patients are needed." @default.
• W3211232292 created "2021-11-08" @default.
• W3211232292 creator A5040710894 @default.
• W3211232292 creator A5044117164 @default.
• W3211232292 creator A5051323066 @default.
• W3211232292 date "2021-11-05" @default.
• W3211232292 modified "2023-10-05" @default.
• W3211232292 title "A multicenter Spanish study of atropine 0.01% in childhood myopia progression" @default.
• W3211232292 cites W1946168984 @default.
• W3211232292 cites W2021560207 @default.
• W3211232292 cites W2026604531 @default.
• W3211232292 cites W2055316773 @default.
• W3211232292 cites W2057383623 @default.
• W3211232292 cites W2094731705 @default.
• W3211232292 cites W2110370370 @default.
• W3211232292 cites W2263395847 @default.
• W3211232292 cites W2263495255 @default.
• W3211232292 cites W2273479788 @default.
• W3211232292 cites W2289808052 @default.
• W3211232292 cites W2336856141 @default.
• W3211232292 cites W2337574702 @default.
• W3211232292 cites W2611968166 @default.
• W3211232292 cites W2728112287 @default.
• W3211232292 cites W2760551522 @default.
• W3211232292 cites W2764248048 @default.
• W3211232292 cites W2782805558 @default.
• W3211232292 cites W2790106734 @default.
• W3211232292 cites W2793810505 @default.
• W3211232292 cites W2820431423 @default.
• W3211232292 cites W2888475023 @default.
• W3211232292 cites W2899636756 @default.
• W3211232292 cites W2900998353 @default.
• W3211232292 cites W2904313905 @default.
• W3211232292 cites W2950088548 @default.
• W3211232292 cites W2950112331 @default.
• W3211232292 cites W2979831316 @default.
• W3211232292 cites W2995569484 @default.
• W3211232292 cites W3008864071 @default.
• W3211232292 cites W3043467522 @default.
• W3211232292 cites W3044355709 @default.
• W3211232292 cites W3081527141 @default.
• W3211232292 cites W3089748349 @default.
• W3211232292 cites W3109159961 @default.
• W3211232292 cites W3110802147 @default.
• W3211232292 cites W3181830557 @default.
• W3211232292 cites W3183185663 @default.
• W3211232292 doi "https://doi.org/10.1038/s41598-021-00923-1" @default.
• W3211232292 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8571279" @default.
• W3211232292 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34741059" @default.
• W3211232292 hasPublicationYear "2021" @default.
• W3211232292 type Work @default.
• W3211232292 sameAs 3211232292 @default.
• W3211232292 citedByCount "11" @default.
• W3211232292 countsByYear W32112322922022 @default.
• W3211232292 countsByYear W32112322922023 @default.
• W3211232292 crossrefType "journal-article" @default.
• W3211232292 hasAuthorship W3211232292A5040710894 @default.
• W3211232292 hasAuthorship W3211232292A5044117164 @default.
• W3211232292 hasAuthorship W3211232292A5051323066 @default.
• W3211232292 hasBestOaLocation W32112322921 @default.
• W3211232292 hasConcept C118487528 @default.
• W3211232292 hasConcept C126322002 @default.
• W3211232292 hasConcept C141071460 @default.
• W3211232292 hasConcept C151956035 @default.
• W3211232292 hasConcept C188816634 @default.
• W3211232292 hasConcept C2775859210 @default.
• W3211232292 hasConcept C2778257484 @default.
• W3211232292 hasConcept C71924100 @default.
• W3211232292 hasConcept C72563966 @default.
• W3211232292 hasConceptScore W3211232292C118487528 @default.
• W3211232292 hasConceptScore W3211232292C126322002 @default.
• W3211232292 hasConceptScore W3211232292C141071460 @default.
• W3211232292 hasConceptScore W3211232292C151956035 @default.
• W3211232292 hasConceptScore W3211232292C188816634 @default.
• W3211232292 hasConceptScore W3211232292C2775859210 @default.
• W3211232292 hasConceptScore W3211232292C2778257484 @default.
• W3211232292 hasConceptScore W3211232292C71924100 @default.
• W3211232292 hasConceptScore W3211232292C72563966 @default.
• W3211232292 hasIssue "1" @default.
• W3211232292 hasLocation W32112322921 @default.
• W3211232292 hasLocation W32112322922 @default.
• W3211232292 hasLocation W32112322923 @default.
• W3211232292 hasLocation W32112322924 @default.
• W3211232292 hasLocation W32112322925 @default.
• W3211232292 hasOpenAccess W3211232292 @default.
• W3211232292 hasPrimaryLocation W32112322921 @default.
• W3211232292 hasRelatedWork W2295722933 @default.
• W3211232292 hasRelatedWork W2315085516 @default.
• W3211232292 hasRelatedWork W2316407790 @default.
• W3211232292 hasRelatedWork W2349999257 @default.
• W3211232292 hasRelatedWork W2354275354 @default.
• W3211232292 hasRelatedWork W2389709268 @default.
• W3211232292 hasRelatedWork W2515762743 @default.
• W3211232292 hasRelatedWork W2531350361 @default.
• W3211232292 hasRelatedWork W2603773853 @default.
• W3211232292 hasRelatedWork W2964295425 @default.
• W3211232292 hasVolume "11" @default.
• W3211232292 isParatext "false" @default.
• W3211232292 isRetracted "false" @default.
• W3211232292 magId "3211232292" @default.

• next